Company / Operating Cash Flow
C4 Therapeutics, Inc. Operating Cash Flow History
FY2022-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Operating Cash Flow
-$98.7M
FY2025
5-year range
-$106.8M / -$87.0M
FY2022-FY2025
Trend
+7.6%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Improved from -$107M to -$99M over the past 2 years.
Based on SEC 10-K filings.
-$99M in FY2025.
Improved from -$107M to -$99M over the past 2 years.
Operating Cash Flow over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Key checks
Key Insights
- In FY2025, operating cash flow increased 7.6% year-over-year.
Company context
Key Data Points
- Altman Z-Score -1.14 (distress zone, below 1.8 threshold)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Operating Cash FlowValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | -$98.7M | +7.6% |
| FY2024 | -$106.8M | +0.0% |
| FY2023 | -$106.8M | -22.9% |
| FY2022 | -$87.0M | - |
As of FY2025 · SEC 10-K · Updated Jun 24, 2026